|Supplied by:||European Collection of Authenticated Cell Cultures (ECACC)|
|Culture Type:||Cell line|
|Collection:||ECACC General Collection|
|Cell Line Name:||H400|
|Citation Guidance:||If use of this culture results in a scientific publication, it should be cited in the publication as: H400 (ECACC 06092006)|
|Keywords:||Human oral squamous cell carcinoma, alveolar process|
|Cell Line Description:||Established from a squamous cell carcinoma (SCC) of the alveolar process (20mm - 40mm) of a female patient aged 55. STNMP stage II, moderately differentiated, node negative tumour. Mutant p53, codon 283 exon 8, C to G wild type K-, N- and Ha-ras. This cell line is highly responsive to TGFbeta. These cells are non-tumourigenic on subcutaneous injection into athymic nude mice, but tumourigenic on injection into the floor of the mouth. Haplotype information: A*11,A*29; B*07,B*15; Cw*03,Cw*15|
|Tissue of Origin:||Alveolar process|
Unless specified otherwise, at the European Collection of Authenticated Cell Cultures (ECACC) we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines. ACDP = Advisory Committee on Dangerous Pathogens (UK)
All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Hyperlinks to MSDS documents:
Frozen cell cultures Material Safety Data Sheet
Growing cell cultures Material Safety Data Sheet
Nucleic acids derived from cell cultures Material Safety Data Sheet
|Subculture Routine:||Split sub-confluent cultures (70-80%) 1:8 to 1:10 using 0.05% trypsin/EDTA; 5% CO2; 37°C. Suggested seeding density 5 x 1000 cells/cm². Cells can take approximately 10 minutes to detach, an alternative is to trypsinise 2 to 3 times with fresh trypsin for shorter periods for each trypsin application. Avoid knocking flasks during the trypsinisation process as this can lead to loss of viability.|
|Culture Medium:||DMEM:HAMS F12 (1:1) + 2mM Glutamine + 10% Foetal Bovine Serum (FBS) + 0.5 ug/ml sodium hydrocortisone succinate|
|Depositor:||Professor Stephen Prime, Department of Oral & Dental Science, Bristol Dental School, University of Bristol, Lower Maudlin Street, Bristol BS1 2LY|
|References:||Prime et al., 1994; Int J Cancer 56, 406-412, Prime et al., 1990; J Pathol 160, 259-269, Prime et al., 1994 Br J Cancer 69, 8-15; Yeudall et al., 1993; Eur J Cancer B Oral Oncol 29B, 63-67 & 1995 31B 136-143|
|Additional Bibliography:||Not Available|
|Patents:||None Specified By Depositor|
|Release Conditions:||Yes - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form.|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Please confirm your country of origin from the list below.